Stay updated on Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The page metadata revision tag updated from v3.6.3 to v3.6.4. This reflects a new revision in the documentation rather than substantive changes to content or features.
    Difference
    0.0%
    Check dated 2026-07-23T11:30:40.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    No Change Detected
  5. Check
    29 days ago
    Change Detected
    Summary
    The page’s revision label was updated to v3.6.3, replacing the previous v3.6.1. This indicates a new release of the page but does not modify the study details or user-facing content.
    Difference
    0.0%
    Check dated 2026-07-02T03:20:40.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The page's revision is updated from v3.6.0 to v3.6.1, indicating a newer release of the page. This update appears to be an administrative metadata change rather than a content change to the study details.
    Difference
    0.0%
    Check dated 2026-06-25T00:17:51.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    Recruitment status updated to 'no longer looking for participants' signals enrollment has ended. The page adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment label, along with a Revision: v3.6.0.
    Difference
    0.1%
    Check dated 2026-06-10T17:57:33.000Z thumbnail image
  8. Check
    58 days ago
    Change Detected
    Summary
    Revision updated from v3.5.4 to v3.5.5, indicating a new edition of the page metadata. There are no changes to the study details or user-facing content.
    Difference
    0.0%
    Check dated 2026-06-03T09:31:32.000Z thumbnail image
  9. Check
    72 days ago
    Change Detected
    Summary
    Publications section now lists the NEJM article by Murthy et al. on tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer with full author names and citation details. The previous NEJM entry that included an erratum has been removed.
    Difference
    0.0%
    Check dated 2026-05-20T06:48:22.000Z thumbnail image

Stay in the know with updates to Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page.